Published in Lab Business Week, January 21st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Spherix.
The tests were done on human subjects to establish the appropriate dosage and timing to be used in the upcoming trial. The company will now recruit patients for the trial, which will take place in Australia and the United States. Company officials expect that the first participants will begin the Phase III...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.